The theoretical class of 2900062L11Rik inhibitors encompasses a range of chemical compounds thought to modulate the activity of the 2900062L11Rik protein indirectly through their influence on cellular signaling pathways and biochemical processes. These inhibitors, not directly targeting 2900062L11Rik, are believed to affect its function via alterations in related cellular mechanisms. The diverse mechanisms of action of these inhibitors reflect the complexity of cellular signaling networks and the multifaceted nature of protein modulation.
Compounds like Lenvatinib and Cabozantinib, which are multi-kinase inhibitors, illustrate the strategy of targeting key enzymes in cell signaling pathways. By altering the phosphorylation state of proteins, these inhibitors can influence various cellular processes including cell proliferation, survival, and angiogenesis, thereby potentially modulating the function of 2900062L11Rik. Similarly, Idelalisib and Everolimus demonstrate the potential of these compounds to affect protein activity by intervening in critical pathways for cell survival and metabolism.
Furthermore, the inhibitor class includes compounds such as Bevacizumab and Olaparib, which target specific aspects of cell function like angiogenesis and DNA repair. These inhibitors impact cellular processes governing protein interactions and cell survival, thus potentially influencing the functional state of 2900062L11Rik. The action of these inhibitors on specific cellular components and processes highlights the indirect approach required to modulate proteins that are not directly associated with these targets.
In summary, the class of 2900062L11Rik inhibitors represents a diverse group of compounds thought to influence the activity of the 2900062L11Rik protein through indirect mechanisms. Their actions, though varied, converge on the common goal of modulating cellular processes and signaling pathways that can impact the function of this protein. The diversity and complexity of these inhibitors underscore the intricate nature of cellular signaling and the nuanced approaches required to indirectly influence protein activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
A multi-kinase inhibitor, potentially impacting signaling pathways related to angiogenesis and cell proliferation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
A Bruton's tyrosine kinase inhibitor, potentially affecting B-cell receptor signaling pathways. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $189.00 | 4 | |
A PI3K inhibitor, known to alter signaling pathways related to cell survival and proliferation. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
An inhibitor of MET, VEGFR, and AXL kinases, potentially affecting cell growth and angiogenesis. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
A JAK inhibitor, impacting signaling pathways related to inflammation and cell proliferation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
An mTOR inhibitor, affecting cell growth, proliferation, and survival pathways. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
An inhibitor of VEGFR, PDGFR, and FGFR, potentially impacting fibrosis and angiogenesis processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A broad-spectrum kinase inhibitor, potentially affecting multiple signaling pathways and protein activities. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor with activity against RAF, VEGFR, and PDGFR, potentially influencing cell growth and angiogenesis. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
A PARP inhibitor, known to impact DNA repair processes and potentially influence protein interactions. | ||||||